Skip to main content
. 2024 Aug 8;9(18):e181906. doi: 10.1172/jci.insight.181906

Figure 3. IL-17B inhibits B cell activation induced by TLRs and IFN-I pathways in vitro.

Figure 3

WT mice spleen B cells were pretreated with rmIL-17B for 12 hours and stimulated with LPS (100 ng/mL), R848 (1 μg/mL), and CpG-1826 (1 μM). (A) CD40, (B) CD69, and (C) CD86 expression at 24 hours. (D) IL-12 and (E) TNF-α mRNA levels at 6 hours. (F) Total (t-) and phosphorylated (p-) p65, p38, JNK, and Erk at 30 or 60 minutes after R848 stimulation. (G) CD40, (H) CD69, and (I) CD86 expression at 24 hours, and (J) MX1, (K) OAS1, and (L) IFIT1 mRNA levels at 6 hours in WT mice spleen B cells pretreated with rmIL-17B for 12 hours and stimulated with IFN-α (1000 U/mL). The data are shown as the mean ± SEM and are representative of 3 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by 1-way ANOVA with Tukey’s multiple-comparison test (A–E and G–I) or 2-way ANOVA with Bonferroni’s mutiple-comparison test (J–L). NS, P > 0.05.